AU2001280093A1 - Method for the prevention and treatment of retinopathy - Google Patents

Method for the prevention and treatment of retinopathy

Info

Publication number
AU2001280093A1
AU2001280093A1 AU2001280093A AU8009301A AU2001280093A1 AU 2001280093 A1 AU2001280093 A1 AU 2001280093A1 AU 2001280093 A AU2001280093 A AU 2001280093A AU 8009301 A AU8009301 A AU 8009301A AU 2001280093 A1 AU2001280093 A1 AU 2001280093A1
Authority
AU
Australia
Prior art keywords
prevention
treatment
retinopathy
retinopathies
various
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280093A
Other languages
English (en)
Inventor
Einar Stefansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001280093A1 publication Critical patent/AU2001280093A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AU2001280093A 2000-08-11 2001-08-10 Method for the prevention and treatment of retinopathy Abandoned AU2001280093A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22435800P 2000-08-11 2000-08-11
US60224358 2000-08-11
PCT/IS2001/000015 WO2002013800A2 (en) 2000-08-11 2001-08-10 Method for the prevention and treatment of retinopathy

Publications (1)

Publication Number Publication Date
AU2001280093A1 true AU2001280093A1 (en) 2002-02-25

Family

ID=22840318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280093A Abandoned AU2001280093A1 (en) 2000-08-11 2001-08-10 Method for the prevention and treatment of retinopathy

Country Status (7)

Country Link
US (1) US20020055458A1 (de)
EP (1) EP1307185B1 (de)
AT (1) ATE292964T1 (de)
AU (1) AU2001280093A1 (de)
CA (1) CA2419158A1 (de)
DE (1) DE60110087T2 (de)
WO (1) WO2002013800A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20060287394A1 (en) * 2003-05-30 2006-12-21 Konstantin Petrukhin Composition and method for treating macular disorders
EP2500031A3 (de) * 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Zusammensetzungen und Verfahren zur Behandlung von Gefäßpermeabilität
US7670794B2 (en) * 2005-11-04 2010-03-02 Washington University Managing glycemia status in diabetic patients
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
PL2106260T3 (pl) * 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
JP6438389B2 (ja) * 2012-05-24 2018-12-12 ネイア メタボリック、インコーポレイテッド 減量法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386098A (en) * 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4677115A (en) * 1984-12-12 1987-06-30 Merck & Co., Inc. Antiglaucoma thieno-thiopyran and thieno-thiepin sulfonamide derivatives, compositions, and method of use thereof
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
CA2323749A1 (en) * 1998-03-06 1999-09-10 William E. Sponsel Composition and method for treating macular disorders
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions

Also Published As

Publication number Publication date
DE60110087D1 (de) 2005-05-19
EP1307185B1 (de) 2005-04-13
ATE292964T1 (de) 2005-04-15
DE60110087T2 (de) 2005-09-29
WO2002013800A2 (en) 2002-02-21
CA2419158A1 (en) 2002-02-21
US20020055458A1 (en) 2002-05-09
EP1307185A2 (de) 2003-05-07
WO2002013800A3 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
WO2004089296A3 (en) Improved inhibitors for the soluble epoxide hydrolase
GEP20084317B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2002076499A3 (en) Combination treatment of pancreatic cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AUPR839001A0 (en) Dosage form, device and methods of treatment
AU2002215261A1 (en) Method and arrangement for treatment of fluid
AU2002367979A1 (en) Devices, systems and methods for reducing levels of pro-inflammartory or anti-inflammatrory stimulators or mediators in blood products
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
WO2003059267A3 (en) SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
WO2002028434A3 (en) Use of a ppar delta activator for treating inflammatory conditions
AU2002231095A1 (en) Method and composition for the treatment of diabetic neuropathy
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PL312908A1 (en) Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
AU2002313364A1 (en) Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
AU2003291368A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
WO2003059332A3 (en) Use of an anti-microtubule agent for the treatment of uveitis
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
AU2811400A (en) Stable formulation containing fumagillin
WO2002024223A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection